Literature DB >> 16609687

Associations of hemodialysis dose and session length with mortality risk in Australian and New Zealand patients.

M R Marshall1, B G Byrne, P G Kerr, S P McDonald.   

Abstract

The optimal combination of hemodialysis (HD) dose and session length remains uncertain, and previous studies have not conclusively shown session length to be an important independent determinant of patient mortality. The objective of this study was to examine associations between HD dose and session length with mortality risk using data from the Australian and New Zealand Dialysis and Transplant Registry. Analyses were performed using a prospective inception cohort comprising all incident adult patients treated by thrice-weekly maintenance HD, who commenced renal replacement therapy with HD between 1 April 1997 and 31 March 2004. In all, 6593 patients were identified, of whom 4193 had sufficient data for multivariate analyses. HD dose (single pool fractional clearance of urea, Kt/V) and session length were included in analyses as those recorded 12 months after HD inception to reduce confounding by residual renal function. The outcome examined was patient mortality. Survival analyses included Kaplan-Meier calculations of survival and Cox regression for multivariate analyses. Covariates in Cox models included patient demographics, co-morbid medical conditions at HD inception, and HD operating parameters. After adjustment for covariates and each other, Kt/V of 1.30-1.39 and session length of 4.5-4.9 h were associated with the lowest mortality risk. There was no interaction between HD dose and session length. Thus, the optimal combination for mortality appears to be Kt/V of > or = 1.3 and session length of > or = 4.5 h. These data suggest a randomized controlled trial to test these hypotheses, and support the inclusion of criteria relating to session length in definitions of adequate HD practice.

Entities:  

Mesh:

Year:  2006        PMID: 16609687     DOI: 10.1038/sj.ki.5000188

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  26 in total

1.  Considerations in the evaluation and determination of minimal risk in pragmatic clinical trials.

Authors:  John D Lantos; David Wendler; Edward Septimus; Sarita Wahba; Rosemary Madigan; Geraldine Bliss
Journal:  Clin Trials       Date:  2015-09-15       Impact factor: 2.486

2.  Cost-effectiveness of frequent in-center hemodialysis.

Authors:  Chris P Lee; Stefanos A Zenios; Glenn M Chertow
Journal:  J Am Soc Nephrol       Date:  2008-07-09       Impact factor: 10.121

3.  Does increased removal of high-molecular-weight toxins improve the survival of hemodialysis patients?

Authors:  Richard A Ward
Journal:  Nat Clin Pract Nephrol       Date:  2008-11-11

4.  Longer dialysis session length is associated with better intermediate outcomes and survival among patients on in-center three times per week hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Authors:  Francesca Tentori; Jinyao Zhang; Yun Li; Angelo Karaboyas; Peter Kerr; Rajiv Saran; Juergen Bommer; Friedrich Port; Takashi Akiba; Ronald Pisoni; Bruce Robinson
Journal:  Nephrol Dial Transplant       Date:  2012-03-19       Impact factor: 5.992

5.  No Survival Benefit in Octogenarians and Nonagenarians with Extended Hemodialysis Treatment Time.

Authors:  Gang Jee Ko; Yoshitsugu Obi; Melissa Soohoo; Tae Ik Chang; Soo Jeong Choi; Csaba P Kovesdy; Elani Streja; Connie M Rhee; Kamyar Kalantar-Zadeh
Journal:  Am J Nephrol       Date:  2018-11-13       Impact factor: 3.754

6.  Disentangling the ultrafiltration rate-mortality association: the respective roles of session length and weight gain.

Authors:  Jennifer E Flythe; Gary C Curhan; Steven M Brunelli
Journal:  Clin J Am Soc Nephrol       Date:  2013-03-14       Impact factor: 8.237

7.  Outcomes associated with in-center nocturnal hemodialysis from a large multicenter program.

Authors:  Eduardo Lacson; Weiling Wang; Keith Lester; Norma Ofsthun; J Michael Lazarus; Raymond M Hakim
Journal:  Clin J Am Soc Nephrol       Date:  2009-12-03       Impact factor: 8.237

8.  Balancing the Evidence: How to Reconcile the Results of Observational Studies vs. Randomized Clinical Trials in Dialysis.

Authors:  Jenny I Shen; Erik L Lum; Tara I Chang
Journal:  Semin Dial       Date:  2016-05-21       Impact factor: 3.455

9.  A framework for analysis of research risks and benefits to participants in standard of care pragmatic clinical trials.

Authors:  Stephanie C Chen; Scott Yh Kim
Journal:  Clin Trials       Date:  2016-06-30       Impact factor: 2.486

10.  Shorter dialysis times are associated with higher mortality among incident hemodialysis patients.

Authors:  Steven M Brunelli; Glenn M Chertow; Elizabeth D Ankers; Edmund G Lowrie; Ravi Thadhani
Journal:  Kidney Int       Date:  2010-01-20       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.